Ferrostatin-1

SKU: orb1300714

Description

Ferrostatin-1

Research Area

Cell Biology

Key Properties

• CAS Number: 347174-05-4
• MW: 262.35
• Purity: >98%
• Formula: C₁₅H₂₂N₂O₂
• SMILES: CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1
• Target: Ferroptosis,Antifungal
• Solubility: Soluble in DMSO (up to 100 mg/ml) or in Ethanol (up to 100 mg/ml).

Bioactivity

• Target IC50:
  HT22 cells:81.2 nM (EC50)|RAW 264.7 cells:0.04 μM (EC50)|IMR-32 cells:18 nM|Ferroptosis:60 nM (EC50, HT-1080 cells)|Lymphocyte:48 nM (EC50)|LLC-MK2 cells:> 240 μM|Fibroblast:33 nM (EC50)|HT1080 cells:95 nM|NIH3T3 cells:0.22 μM
• In Vivo:
  METHODS: To investigate whether iron death is associated with LPS-induced acute kidney injury (AKI), Ferrostatin-1 (5 mg/kg) was administered intraperitoneally in a single dose to C57BL/6 mice, and infectious AKI was induced by intraperitoneal injection of LPS (10 mg/kg) 30 min later. RESULTS: Ferrostatin-1 significantly protected mice from renal dysfunction and tubular injury in LPS-induced AKI. METHODS: To investigate whether iron disorders are associated with acute liver disease and its molecular mechanism, Ferrostatin-1 (2.5 μM/kg) was intraperitoneally injected into ICR mice once a day for three days, followed by intraperitoneal injection of TAA (250 mg/kg/day) for three consecutive days, to establish an acute liver injury (ALI) model in mice. RESULTS: Ferrostatin-1 pretreatment significantly reduced TAA-induced changes in plasma ALT, AST and LDH levels, inhibited the expression of TfR1, Fpn and Ft-L proteins, and decreased iron accumulation without affecting the expression of xCT or GPX4 in the liver. Ferrostatin-1 prevents hepatic iron by decreasing death.
• In Vitro:
  METHODS: Human bronchial epithelial cells BEAS-2B were co-treated with LPS (10 mg/L) and Ferrostatin-1 (2 μM) for 16 h. The growth inhibition of the cells was detected by CCK-8 method. RESULTS: Ferrostatin-1 attenuated the LPS-induced cell damage. METHODS: Human fibrosarcoma cells HT-1080 were treated with Ferrostatin-1 (0.5 μM) and Erastin (10 μM) for 4 h, and ROS levels produced by the cells were measured by Flow Cytometry. RESULTS: Ferrostatin-1 inhibited the Erastin-induced accumulation of cytoplasmic and lipid ROS. METHODS: Mouse hippocampal neuronal cells HT-22 were treated with Ferrostatin-1 (3-12 μM) for 16 h, then treated with 5 mM glutamate for 24 h, and then LDH release was measured. RESULTS: The release of LDH was significantly increased by treatment with glutamate, and the release of LDH was inhibited by Ferrostatin-1 treatment.
• Cell Research:
  Cell viability was typically assessed in 384-well format by Alamar Blue fluorescence (ex/em 530/590) measured on a Victor3 plate reader. In some experiments, Trypan Blue dye exclusion counting was performed using an automated cell counter. Cell viability under test conditions is reported as a percentage relative to the negative control treatment .

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Fungal, Fer 1, Fer1, Fer-1, Ferroptosis, Ferrostatin 1, Ferrostatin1, Ferrostatin-1, Ferrostatin-1 (Fer-1), Inhibitor, neurotoxicity, inhibit, cytosolic, death, cell, antifungal, antioxidant, ROS

Compound Identifiers

PubChem CID

4068248